Menu

Infographic: Exploring New Therapeutic Targets in ALS

Biological insights from the last decade of research on amyotrophic lateral sclerosis are revealing novel opportunities for treatment.

Sep 1, 2018
Jenny Rood

ABOVE: KOTO FEJA

Research over the last 10 years has unveiled numerous disease mechanisms in amyotrophic lateral sclerosis (ALS), most of which act in motor neurons. These new insights into ALS biology are allowing drug developers to shift from focusing on downstream targets and pathways, such as inflammation or muscle weakness, to upstream mechanisms more likely to drive the disease.

Therapies currently under development may target one of several processes linked to ALS, including:

1 Inflammation of the cell body

2 Aggregation of proteins in the cell cytoplasm

3 Defects in nuclear pore complexes 

Dysregulation of mRNA processing

5 Dysregulation of microRNAs 

the scientist staff

Read the full story

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.